Drugmakers and distributors will begin to see extra costs and regulatory hurdles late next year under a new Russian law that expands drug quality certification requirements.
Russia’s new regulatory procedures under Federal Law No. 449-FZ govern distribution of medical products, and include requirements to test medicines regularly, submit test reports to the drug regulator Roszdravnadzor, and other new provisions directed an ensuring drugs released on the market are safe and effective.
“Based on the new law, control for releasing medicines...
For more stories, analysis and expertiseOR Request Trial